Announcement no. 29/2025
7 July 2025
Reykjavik, Iceland/Copenhagen, Denmark, 7 July 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025.
During the period 30 June to 4 July 2025 Embla Medical has acquired 46,300 shares under the Program at the average price of DKK 33.98. Following the transactions below, the Company holds 1,659,724 shares, corresponding to 0.39% of the Company’s total share capital.
| Transaction date | No. of shares | Avg. purchase price in DKK | Transaction value in DKK | |
| 30 June 2025 | 11,500 | 33.95 | 390,469 | |
| 1 July 2025 | 10,500 | 34.00 | 357,000 | |
| 2 July 2025 | 9,500 | 33.99 | 322,868 | |
| 3 July 2025 | 7,400 | 34.00 | 251,600 | |
| 4 July 2025 | 7,400 | 33.99 | 251,493 | |
| Total | 46,300 | 33.98 | 1,573,430 |
The purpose of the Program is to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Capital Allocation Policy. The Program will end no later than 31 December 2025, but the Company is entitled to discontinue the Program at any time.
The Company may purchase up to 2,000,000 shares under the Program, corresponding to 0.47% of the current share capital. The total consideration for shares purchased under the Program shall not exceed USD 10 million.
The Program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (“MAR”), and the Commission’s delegated regulation 2016/1052.
Further information
Klaus Sindahl, Head of Investor Relations, KSindahl@emblamedical.com, +45 5363 0134
Embla Medical press releases by e-mail
If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors
About Embla Medical
Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in Reykjavik in 1971 with the mission to improve people’s mobility. Embla Medical is home to several brands renowned for positively impacting people’s health and well-being. They include Össur, a leading global provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park Industries, creators of custom-built prosthetic solutions. Embla Medical also provides patients with world-class care through a global network of Orthotic and Prosthetic (O&P) facilities. Embla Medical is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women’s Empowerment Principles, and contributes to the UN Sustainable Development Goals. The company’s climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has more than 4,000 employees. www.emblamedical.com
Embla Medical was formerly listed as Össur (OSSR) on Nasdaq Copenhagen until 8 April 2024.